Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
FAQs
Advertise
UsernamePublicRestriction
Tags:
Human Capital Leadership Business Strategies

Taking Action On Diversity, BIO Challenges CEOs To Pursue Business Benefits

  • Interviews

Executive Summary

Scrip spoke with Halozyme CEO Helen Torley, chair of BIO's Workforce Development, Diversity and Inclusion committee, about efforts to communicate the benefits of diverse leadership to CEOs and build a database of diverse board candidates.

You may also be interested in...



Leading A Diverse Company: Biopharma Executives Offer Ways Forward

BIO hosted discussions during its annual meeting to reinforce the value of inclusion, offer advice to companies and reflect on recent US events.

Leading A Diverse Company: Biopharma Executives Offer Ways Forward

BIO hosted discussions during its annual meeting to reinforce the value of inclusion, offer advice to companies and reflect on recent US events. 

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Table

View full table

Topics

Related Companies

Tags:
Human Capital Leadership Business Strategies
UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By